Treatment of Moderate to Severe Glabellar Lines: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Treatment of Moderate to Severe Glabellar Lines (NCT04249583), a randomized phase 3 study. The primary outcome is Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown at One Month..

2. Clinical Question

This question concerns a defined assessment outcome at a specified follow-up, rather than every possible change in appearance, experience, or safety. The endpoint requires improvement on the investigator and subject assessments, as stated in its title. The registry record does not report further operational detail about how the two assessments were combined to determine whether a participant met the endpoint.

3. Trial Design

This was a phase 3, randomized, parallel-group study with quadruple masking and a placebo control. Its official title describes a multicenter, randomized, double-blind, placebo-controlled study of QM1114-DP for moderate to severe glabellar lines. The registry status is completed. The recorded study start was 2020-02-10, and primary completion was 2020-08-07.

The treatment group received QM1114-DP, a Botulinum Toxin Type A, by intramuscular injection. The placebo group received a buffered solution by the same route. The study objective was to evaluate efficacy and safety for a single dose. Randomization is intended to support a fair comparison by allocating participants to groups through chance rather than by choosing a treatment based on their characteristics. Masking is intended to limit the influence of treatment knowledge on participants, study personnel, or assessment; the registry record identifies quadruple masking but does not specify the roles covered by each masking level.

The registry lists an enrollment of 300. The primary endpoint results are reported for 199 treatment participants and 67 placebo participants. Those outcome denominators need not be identical to the enrollment figure: an outcome denominator reflects the participants included in that particular result, and the registry record does not explain the flow from enrollment to endpoint analysis. The safety counts use different denominators, which are described in the safety discussion.

The primary endpoint is assessed at one month. The record also lists one secondary outcome concerning the investigator scale at maximum frown. Further details about the allocation procedure, site-specific enrollment, eligibility criteria, and analysis populations are not reported in the registry record. The design establishes the intended comparison, but interpretation of results still depends on the endpoint definitions, available observations, and statistical methods actually used.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown at One Month., measured over One Month.

The primary endpoint counts participants with at least a two-grade improvement from baseline on the Glabellar Lines Investigator and Subject Assessments at maximum frown, assessed at one month. The assessment uses a four-grade scale, where 0 means none and 3 means severe. The endpoint is binary: each participant either meets the improvement criterion or does not, and the result is expressed as a count of participants.

An endpoint of this kind turns a graded assessment into a clinically interpretable response category. It asks whether a participant crossed a specified improvement threshold, rather than describing the average score change or the full distribution of scores. Such a threshold can make a comparison easier to communicate, while also discarding detail: participants with different score changes may be grouped together if they fall on the same side of the threshold.

The title names both investigator and subject assessments. This makes the endpoint dependent on two forms of assessment, but the registry record does not report the exact rule used to combine them, how baseline and follow-up ratings were paired, or how missing ratings affected endpoint status. Those details matter when interpreting what a successful response represents. The registry result should therefore be read according to the stated criterion, without assuming additional scoring or adjudication procedures.

7. Results Posted in the Registry

• Treatment: 82.9% (165/199) versus 0.0% (0/67) on control; risk difference 82.9 percentage points (95% CI 77.7 to 88.1); unadjusted two-proportion z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Percentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Treatment: 96.4% (187/194) versus 4.7% (3/64) on control; risk difference 91.7 percentage points (95% CI 85.9 to 97.5), risk ratio 20.56 (6.81–62.09); unadjusted two-proportion z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically higher for Treatment than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The registry lists one secondary outcome, based on the investigator scale at maximum frown, and its posted pattern is in the same broad direction as the primary endpoint. This offers related context because both outcomes concern glabellar-line assessments at maximum frown. They are not identical measures: the primary outcome refers to improvement on investigator and subject assessments, while the secondary outcome uses the investigator scale and a stated score threshold.

The secondary result should be considered alongside, not as a substitute for, the primary endpoint. Similar direction across related outcomes can make the overall pattern easier to understand, but it does not establish that the outcomes are independent confirmations. They may draw on overlapping participants, related ratings, and a common follow-up timeframe. The registry record does not report the relationship between the analyses or a plan for interpreting the secondary outcome in light of the primary result.

Unadjusted secondary results carry less weight when several outcomes may be examined. General explanation: testing multiple outcomes creates more opportunities for apparently strong findings to arise by chance, even if each individual test uses a conventional threshold. Methods that control multiplicity can address this issue, but the registry record does not report whether any adjustment or hierarchical testing strategy was used. This does not invalidate the secondary result; it means its p-value and interval, if considered, should be interpreted with awareness of the broader set of comparisons.

The record lists one secondary outcome, but does not report a multiplicity plan, the full family of outcomes considered, or whether other analyses were conducted but not posted. Accordingly, the secondary evidence is best treated as supportive descriptive context rather than definitive independent confirmation. Its interpretation should remain tied to its own outcome definition and the limitations of the registry’s analysis details.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Percentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown

9. Statistical Interpretation

10. Statistical Methods Explained

For a binary endpoint, each participant is classified as having or not having the specified event. In this trial, the event is meeting the primary improvement criterion at one month. The posted counts are 165 of 199 in the treatment group and 0 of 67 in the placebo group. A response proportion describes the fraction of an analyzed group that met the criterion. Comparing these proportions focuses on the frequency of the endpoint, rather than on the magnitude of score changes among participants.

What does the risk difference express?

The risk difference subtracts the comparison-group response proportion from the treatment-group response proportion. It is an absolute contrast, expressed on the probability scale. The recalculated unadjusted risk difference is 0.829. In plain terms, this is the estimated separation between the two observed response proportions under that calculation. It is not a relative measure, and it does not imply that every participant experiences the same outcome.

A risk difference is often useful when the question is how much the event frequency differs between groups. It remains tied to the endpoint definition and the groups included in the analysis. It can also be affected by missing outcome data or differences between the analyzed groups that randomization alone does not remove in the observed dataset. The registry record does not provide enough detail to assess those possibilities fully.

What does the confidence interval add?

A confidence interval gives a range of values compatible with the observed data under the statistical method and its assumptions. The posted 95% interval for the recalculated risk difference is 0.777 to 0.881. General explanation: intervals are useful because a single estimate does not show its sampling uncertainty. A narrower interval indicates greater precision under the method used, while a wider interval indicates more uncertainty. The interval does not guarantee that the true value lies within its particular limits, nor does it account automatically for biases, missing data, or choices made in study conduct.

How should the p-values be read?

The unadjusted recalculation reports p<0.001. General explanation: a p-value measures how unusual data at least as incompatible with a specified null hypothesis would be if that null hypothesis and the model assumptions were correct. It is not the probability that the null hypothesis is true, and it does not measure the size or practical importance of an effect. The registry’s sponsor-reported analysis gives p=0.05 using the Cochran-Mantel-Haenszel method. That method can combine comparisons across strata, but the registry record does not identify the strata or give enough details to reproduce the analysis. The two p-values therefore describe different reported calculations and should not be conflated.

Why does a zero event count need care?

The placebo count is zero for the primary endpoint. General explanation: a zero observed count does not prove that the underlying event probability is zero. It can also make relative measures unstable or difficult to estimate, since a relative comparison depends on a nonzero reference rate. The absolute risk difference remains calculable from the reported group proportions, and its confidence interval communicates uncertainty in that contrast. The registry record provides no reported primary relative risk or odds ratio.

What is the role of the planning illustration?

The posted sample-size illustration is a planning exercise based on the observed secondary-outcome effect, not the original trial design. It assumes a two-sided significance level of 0.05, equal allocation, and a normal approximation, and gives participants per arm for 80% or 90% power at the stated fractions of the observed effect. General explanation: such calculations estimate the group sizes that a future study might need under the chosen assumptions. They are not observed power, do not establish the adequacy of this completed trial, and should not be mistaken for the actual enrollment rationale. The trial’s own sample-size justification is not reported in the registry record.

11. Confidence Intervals and Precision

The primary unadjusted risk difference is 0.829, with a 95% confidence interval from 0.777 to 0.881. This interval gives a measure of the statistical precision of the recalculated contrast. Its limits are both well above zero, so the estimated direction and size of the unadjusted contrast are not driven only by a point estimate with a wide range spanning no difference. The interval nevertheless remains conditional on the calculation, data, and assumptions used.

Precision is not the same as freedom from bias. A confidence interval does not correct for missing outcomes, unreported analysis choices, deviations from the intended design, or differences in how assessments were made. The registry record does not describe the handling of missing primary outcomes or provide the analysis-population definition. Thus the interval summarizes sampling uncertainty for the posted recalculation, not every source of uncertainty relevant to the trial.

The zero event count in the placebo group deserves particular attention. The observed count is clear, but it does not make the underlying placebo response probability known without uncertainty. The difference interval is an absolute comparison; it does not eliminate uncertainty about each group’s underlying response probability. The result is also specific to the one-month measurement and the stated threshold-based endpoint.

The sponsor-reported Cochran-Mantel-Haenszel analysis gives p=0.05, whereas the unadjusted recalculation gives p<0.001. These values do not convey the same information: a p-value is not a measure of precision or effect magnitude, and a p-value alone does not replace an interval estimate. The registry record does not report an interval for the sponsor’s analysis, nor the details needed to reproduce it. The sponsor analysis and recalculation should therefore be read with their methods clearly distinguished.

12. Analyses Reported by the Sponsor

The registry reports a sponsor analysis comparing treatment and placebo using the Cochran-Mantel-Haenszel method, with p=0.05. Separately, the simple unadjusted recalculation from the posted primary counts estimates a risk difference of 0.829, with a 95% confidence interval from 0.777 to 0.881 and p<0.001. The p-values differ, and the registry record does not supply the analysis details needed to reproduce the sponsor result or explain the difference.

The Cochran-Mantel-Haenszel method is generally used to combine comparisons across strata. The unadjusted recalculation compares the overall response proportions without such stratification. If the analyses use different methods, populations, or assumptions, their outputs need not match. The record does not say which specific factors were used for stratification, how missing observations were handled, or how the reported test was implemented. It is therefore not possible to attribute the difference to a particular cause based on the registry record alone.

The posted sponsor analysis should be described as reported, and the recalculation as an unadjusted analysis of the posted summary counts. Neither should be recast as the other. The risk difference and interval convey the magnitude and precision of the recalculated contrast; the sponsor p-value is a separate test result. The registry record does not provide a sponsor-reported effect estimate or confidence interval for direct comparison with the recalculation.

13. Multiplicity, Missing Data and Analysis Populations

The registry record does not report how multiplicity was handled. It lists one primary endpoint and one secondary outcome, but does not describe a testing hierarchy, an adjustment across outcomes, or the family of hypotheses considered. General explanation: when several outcomes or analyses are tested, the chance of obtaining at least one apparently unusual result can increase. A prespecified multiplicity strategy can help control that issue. Without a reported strategy, the secondary result should be treated as exploratory or supportive rather than as a fully adjusted confirmatory test. The record does not establish whether a strategy existed outside the posted information.

Missing-data handling is also not reported in the registry record. The primary endpoint counts use denominators of 199 for treatment and 67 for placebo, while the registry lists an enrollment of 300. These figures describe different aspects of the record; the available information does not explain the participant flow or why the outcome denominators take those values. No imputation method, missingness assumption, or sensitivity analysis is reported. It is not possible to determine from the record whether missing assessments were excluded, classified in another way, or addressed through another procedure.

The analysis populations are not described. The registry record does not state whether the primary comparison used all randomized participants, participants with an evaluable assessment, or another defined population. That distinction can matter because excluding participants after randomization may affect the balance created by random allocation. The endpoint population field is blank, and no further definition is posted.

The record reports a sponsor analysis using the Cochran-Mantel-Haenszel method but does not state the strata or provide enough methodological detail to reproduce it. It also does not report interim analyses, stopping rules, or the trial’s sample-size justification. These omissions limit how fully the reported test can be assessed; they are not evidence that any particular procedure was or was not used.

14. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 2% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: gastroesophageal reflux disease (1.3%), alcoholic pancreatitis (0.5%), pancreatitis (0.5%), upper gastrointestinal haemorrhage (0.5%), appendicitis (0.5%).

The registry reports serious adverse events for 5 of 222 participants in the treatment group and 1 of 75 in the placebo group. Other adverse events are reported for 8 of 222 in the treatment group and 2 of 75 in the placebo group. The posted death count is 0 in each group. These are counts and denominators as recorded for safety; they are not the same denominators as those used for the primary endpoint.

The serious-event terms listed include Gastroesophageal reflux disease at 1.3%, and Alcoholic pancreatitis, Pancreatitis, Upper gastrointestinal haemorrhage, Appendicitis, and Cellulitis at 0.5% each. These terms and percentages describe the registry’s listing; they should not be read as proof that the intervention caused an event. The record does not provide enough detail to assess event timing, severity beyond the serious classification, relatedness, or how repeated events were handled.

Safety counts are descriptive. Differences in counts alone do not establish a causal safety effect, particularly without further information about exposure, follow-up, event definitions, and analysis methods. The posted figures should be interpreted as the adverse-event information recorded for the trial, not as a complete assessment of risks outside its study context.

15. What the Result Does, and Does Not, Mean

The primary result describes a substantial observed separation in the proportion meeting the stated improvement criterion at one month: 165 of 199 treatment participants and 0 of 67 placebo participants. The unadjusted risk difference is 0.829, with a 95% confidence interval from 0.777 to 0.881. These figures summarize the posted outcome and its statistical uncertainty under the recalculation. They do not establish that every participant had the same experience or that the effect was identical for every type of glabellar-line assessment.

The result is specific to a single-dose comparison of QM1114-DP with placebo, to the endpoint definition, and to the one-month assessment. It does not tell readers how long the measured response persisted, whether outcomes differed at other times, or how the result relates to measures not listed in the registry record. The endpoint uses a threshold on assessments, so it also does not show the full distribution of score changes or the size of improvement among participants who met the criterion.

The result does not prove the underlying placebo response probability is zero. It also does not answer whether treatment is appropriate for any individual or provide medical advice. Safety counts are separate descriptive findings, and they do not establish that an adverse event was caused by treatment.

Finally, the registry leaves important analytical details unreported, including the primary analysis population, missing-data handling, and the details behind the sponsor-reported Cochran-Mantel-Haenszel test. The unadjusted recalculation and sponsor result should therefore remain distinct. The posted data support an interpretation of the observed comparison, but they do not resolve every question about analysis choices, generalizability, durability, or safety.

16. Why This Trial Matters Statistically

This trial illustrates why a binary clinical endpoint should be read with both its group counts and its effect estimate. The counts show how many participants met a clearly stated threshold, while the risk difference translates the contrast into an absolute comparison. The confidence interval adds information about precision that a point estimate alone cannot provide. Together, these statistics describe more than a p-value can.

The zero response count in the placebo group also highlights a common issue in binary-outcome analysis. A zero in a finite sample is an observed result, not proof of a zero underlying probability. Absolute differences can still be estimated, while relative measures can become difficult to interpret when a comparison group has no observed events. Understanding that distinction helps prevent overstatement.

The registry’s sponsor-reported Cochran-Mantel-Haenszel p-value and the unadjusted recalculated p-value differ. This makes transparent reporting of estimands, analysis populations, stratification, and missing-data methods especially important. Without those details, readers cannot fully reproduce or reconcile analyses. The record also leaves multiplicity and sample-size justification unreported, limiting assessment of how confirmatory claims were organized.

Finally, the primary and secondary outcomes are related but not interchangeable, and safety counts use different denominators from the primary outcome. Keeping these distinctions visible is central to sound statistical interpretation. The trial is informative about its posted endpoint comparison, while its registry record also demonstrates how methodological details shape the strength and limits of conclusions.

17. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations are specific to the information recorded for this trial. The primary endpoint title refers to both investigator and subject assessments, but the registry record does not describe the rule for combining those ratings or the handling of incomplete paired assessments. The endpoint result is therefore interpretable at the stated level, but important operational details are unavailable.

The primary outcome denominators differ from the enrollment figure, and the record does not explain the participant flow into the endpoint analysis. It does not report the analysis population, reasons for unavailable outcomes, missing-data procedures, or sensitivity analyses. These omissions prevent a full assessment of whether the reported groups represent all randomized participants or a subset with available measurements.

The sponsor-reported Cochran-Mantel-Haenszel analysis is accompanied by p=0.05, but the strata and implementation details are not reported. The unadjusted recalculation yields a different p-value; the available record does not allow the cause of that difference to be established. No sponsor effect estimate or confidence interval is listed for direct comparison.

The registry does not report multiplicity handling for the secondary outcome, a sample-size justification, interim analyses, or stopping rules. Follow-up beyond the one-month primary timeframe is not described in the outcome information. Safety denominators differ from the endpoint denominators, and details needed to judge event attribution and timing are not reported. These are limits on interpretation of the registry record, not evidence that unreported procedures were absent.

18. Related Tutorials

19. Related Statistical Calculators

20. Sources

• ClinicalTrials.gov: Treatment of Moderate to Severe Glabellar Lines — NCT04249583.
• Registry record last updated 2023-06-18; status last verified 2022-09.
• Results first posted 2023-06-18.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

21. Record Summary

NCT04249583 is a completed phase 3 randomized, quadruple-masked, parallel-group, placebo-controlled study of QM1114-DP for moderate to severe glabellar lines. It lists an enrollment of 300 and evaluates a single dose administered by intramuscular injection. Primary completion was recorded as 2020-08-07.

At one month, the primary outcome counts were 165 of 199 in the treatment group and 0 of 67 in the placebo group. The unadjusted recalculated risk difference is 0.829, with a 95% confidence interval from 0.777 to 0.881 and p<0.001. The sponsor-reported Cochran-Mantel-Haenszel analysis gives p=0.05. The record does not report enough detail to reproduce that analysis or explain the difference.

One secondary outcome and safety results are also listed. The analysis population, missing-data approach, multiplicity strategy, and sample-size justification are not reported in the registry record. Interpretation should distinguish the observed endpoint counts, the unadjusted recalculation, and the sponsor-reported analysis.